Clinical trial
Effect of Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, on Ventricular Repolarization Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study
NCT06721442 is registered in ClinicalTrials.gov with Beneficência Portuguesa de São Paulo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, on Ventricular Repolarization Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study
- Lead sponsor
- Beneficência Portuguesa de São Paulo
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 10, 2023
- Completion date
- July 10, 2024
- Enrollment
- 174 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.